FDA re­view­ers plot case for ran­dom­ized da­ta on blood can­cer PI3K in­hibitors ahead of ad­vi­so­ry meet­ing

The fate of fu­ture de­vel­op­ment of the PI3K in­hibitor class, in hema­to­log­ic ma­lig­nan­cies, will be de­cid­ed on Thurs­day as the FDA’s out­side ad­vi­sors meet to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER